论文部分内容阅读
我组于1970年开始哮喘菌苗注射治疗,收到初步效果。现就45岁以上的103例疗效观察小结如下:病历来源:我市工厂、企业职工、街道居民和郊区农民。一、诊断标准和依据:1.既往有慢性咳、痰、喘史,反复发作,冬季加重。2.除外其他心肺疾病(如活动性肺结核、尘肺,较明显支气管扩张、风心病、高心病等)。3.经常或感冒后吐黄痰者定为合并感染。4.活动后气喘,并有桶胸、呼吸音减弱,或胸片显示肺气肿征者定为合并肺气肿。二、菌苗来源:北京生物制品研究所生产的(705-6)甲链,白葡,奈氏灭活菌苗。菌苗浓度每毫升含菌9亿个。三、注射方法和剂量:每周皮下注射一次,第一次0.1毫升,第二次0.2毫升,第三次0.3毫升,第
My group began asthma vaccine injections in 1970, received initial results. Now over the age of 103 103 cases of efficacy summary are as follows: Medical records Source: My factory, business workers, street residents and suburban farmers. First, the diagnostic criteria and basis: 1. Past chronic cough, sputum, asthma history, recurrent, increased winter. 2. Except for other cardiopulmonary diseases (such as active tuberculosis, pneumoconiosis, more obvious bronchiectasis, rheumatic heart disease, heart disease, etc.). 3. Often or after a cold vomit sputum were identified as co-infection. 4. Activities after asthma, and a barrel chest, breath sounds weakened, or chest X-ray showed signs of emphysema with pulmonary emphysema. Second, the source of vaccine: Beijing Institute of Biological Products produced (705-6) A chain, white Portugal, Neisseria inactivated vaccine. Bacterial concentration of 900 million bacteria per ml. Third, the injection method and dose: once a week subcutaneous injection, the first 0.1 ml, the second 0.2 ml, the third 0.3 ml, the first